RxDoctor Payments Data

Amanda Robinson

Family · Tupelo, MSNPI 1891233458

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $12,044 of the $14,974 with a category attached, or 80.4%. It is spread thinly across 43 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $5,663 and has fallen 57.1% since, to $2,427 in 2025. Among family clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,974in general payments, 2019–2025

Across 720 payments — averaging $20.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insulet Corporation$4K
  • Lilly USA, LLC$2K
  • Novo Nordisk$1K
  • Xeris Pharmaceuticals, Inc.$1K
  • Amgen$991
  • Abbott$828
  • plus $6K from 37 others

What the payments were for

  • Speaking & faculty fees$2,80019%
  • Food & beverage$12,04480%
  • Gifts$1301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,974 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide376$465,055
MounjaroTirzepatide193$204,159
JardianceEmpagliflozin211$176,577
Tresiba Flextouch U-200Insulin Degludec100$121,161
TrulicityDulaglutide94$107,622
Tresiba Flextouch U-100Insulin Degludec154$86,742
Humulin R U-500 KwikpenInsulin Regular, Human31$56,459
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog30$50,248
FarxigaDapagliflozin Propanediol59$47,426
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp127$37,036
Novolog FlexpenInsulin Aspart150$36,108
Humulin R U-500Insulin Regular, Human23$35,456
Fiasp FlextouchInsulin Aspart (Niacinamide)52$32,779
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/713$29,618
FiaspInsulin Aspart (Niacinamide)32$22,988

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Fiasp, Novolog, Novolog Mix 70-30$1,113$512,200482 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$1,511$318,581315 claims
Boehringer IngelheimJardiance, Synjardy Xr, Synjardy$472$195,119234 claims
AstraZenecaFarxiga$207$47,42659 claims
MerckJanuvia, Janumet Xr$86$32,65831 claims
AbbVieLinzess$579$6,95413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.

Other family in Tupelo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →